Short Wave Folgen

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent Jon Hamilton explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.Additional links:- Jon's reporting on aducanumab: https://n.pr/3bDV0MY- Jon's reporting on future Alzheimer's treatments: https://n.pr/3bDUsqoYou can always reach the show by emailing shortwave@npr.org.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

When people can't afford rent, they often end up in closer quarters. NPR health policy correspondent Selena Simmons-Duffin shares two stories from her reporting and the research being done on housing and eviction policies in the US. For more of Selena's reporting, check out "Why helping people pay rent can fight the pandemic" (https://n.pr/3BIluHt).Follow Selena on Twitter @SelenaSD. You can email Short Wave at ShortWave@NPR.org.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In 1977, NASA sent out two Voyager probes to study Jupiter and Saturn. The spacecrafts were designed to last about five years, but they are still, to this day, collecting and sending back data from beyond the solar system. But the Voyager mission is living on borrowed time. Today NPR science correspondent Nell Greenfieldboyce talks about a proposal for an intentionally long mission - what it would take for NASA to actually plan for an interstellar voyage that would pass research and responsibility down through generations.What would you put on a spacecraft bound for the stars? Email the show at shortwave@npr.org!Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy